°®¶¹´«Ã½

°®¶¹´«Ã½. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration (FDA) on March 11 (U.S. Eastern Standard Time) for a five-day dosing regimen of the hypo-methylating agent Dacogen® (generic name: decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS).

Dacogen® was approved by the FDA in May 2006 as a treatment for MDS. The product has been marketed by Eisai Inc. since January 2008 in the United States.

The previously approved dosing regimen for Dacogen® is administered at a dose of 15mg/m₂ by continuous intravenous infusion over three hours repeated every eight hours for three consecutive days per cycle and repeated every six weeks. The newly approved five-day dosing regimen will be administered at a dose of 20mg/m₂ by continuous intravenous infusion over one hour repeated daily for five days per cycle. The cycle is repeated every four weeks.

The approval of the new five-day dosing regimen offers patients with MDS and healthcare professionals the flexibility of choosing the appropriate dosing regimen. It is also expected to make a contribution in outpatient treatment with reduced infusion time.

MDS is a potentially life-threatening group of bone marrow diseases that alter the production of functional blood cells. Over time, MDS can progress to acute myelogenous leukemia. In the United States, between 10,000 and 15,000 new cases of MDS are diagnosed each year.

Eisai has been conducting clinical development of an additional dosing regimen of Dacogen® in order to address the unmet medical needs of patients with MDS and healthcare professionals. By providing the newly approved five-day dosing regimen as an alternative treatment option, Eisai will continue to make contributions to increasing benefits for patients living with MDS.